The glucocorticoid receptor (GR) is a ligand-activated transcription factor that belongs to the nuclear hormone receptor superfamily. Glucocorticoids (GC) are widely used to treat a broad range of inflammatory disorders and inhaled GCs are a well-established class of drugs for the control of asthma. However, prolonged use at the highest approved doses increases the risk of target related adverse effects. This presentation describes the discovery of AZD7594, an inhaled novel non-steroidal GR modulator that is in clinical development for asthma. Structural data were used to both drive the design and to build mechanistic insight into the function of the receptor.
Karl Edman, Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal, SE 43183, Sweden
A short speaker biography:
Karl Edman is associate principal scientist at the structure and biophysics department at AstraZeneca, Gothenburg. He has supported a broad range of projects across several disease areas with structural information and mode of action studies and works as a Discovery Sciences project coordinator.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.